Update on Treatment and Prevention of Chronic Antibody Mediated Rejection in Renal Transplant Recipients

저자(들)

  • Salman Tahir Shafi Sharif Medical and Dental College, Lahore

##semicolon##

https://doi.org/10.53778/pjkd40353

##semicolon##

Rejection, kidney transplant##common.commaListSeparator## acute rejection##common.commaListSeparator## chronic rejection##common.commaListSeparator## antibody mediated rejection##common.commaListSeparator## complement,##common.commaListSeparator## plasmapheresis##common.commaListSeparator## Bortezomib,##common.commaListSeparator## Rituximab##common.commaListSeparator## Eculizumab##common.commaListSeparator## Tocilizumab

초록

Chronic antibody mediated rejection (AMR) is a major cause of allograft failure1,2. Chronic AMR clinically presents with proteinuria and gradual decline in renal function. The underlying mechanisms of AMR include both antibody mediated complement-dependent cytotoxicity, complement-independent cellular cytotoxicity and other mechanisms. The purpose of this review is to appraise recent literature on diagnosis, treatment and prevention of chronic AMR.

PJKD

##submission.downloads##

출판됨

2021-01-31

권

호. 4 번호. 03 (2020): Pakistan Journal of Kidney Diseases

세션

Review Article

##submission.license##

##submission.copyrightStatement##

##submission.license.cc.by-nc4.footer##

##submission.howToCite##

Update on Treatment and Prevention of Chronic Antibody Mediated Rejection in Renal Transplant Recipients. (2021). Pakistan Journal of Kidney Diseases, 4(03). https://doi.org/10.53778/pjkd40353